Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate panel moves meth bill

This article was originally published in The Tan Sheet

Executive Summary

The Senate Judiciary Committee approves legislation to prevent mass purchases of methamphetamine precursors by facilitating use of electronic logbooks in pharmacies through state and local government grants, according to bill co-sponsor Sen. Chuck Grassley, R-Iowa. The Methamphetamine Production Prevention Act of 2007, S. 1276, aims to stop "smurfing" - buying nonprescription, pseudoephedrine-containing cold or allergy remedies in small quantities at multiple pharmacies - by making "electronic logbook systems far more cost-effective without hurting law enforcement efforts," Grassley says in a Sept. 11 release. The bill was introduced in May 2007 by Sen. Dick Durbin, D-Ill., to add the electronic logbook provision omitted by 2006's Combat Meth Act (1"The Tan Sheet" May 7, 2007, p. 3). A companion bill, H.R. 2747, has not moved since being referred to a House Judiciary subcommittee in July 2007 (2"The Tan Sheet" June 25, 2007, In Brief). Several states, including Arkansas and Iowa, have introduced their own e-tracking systems (3"The Tan Sheet" June 9, 2008, In Brief)

You may also be interested in...



Durbin Introduces Pseudoephedrine Electronic Log Bill To Fight Smurfing

A bill introduced in Congress May 3 funds the creation of electronic databases to record pseudoephedrine purchases, in an effort to improve enforcement of existing methamphetamine precursor control laws

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel